Abstract
Objective. A systemic review of current literature on the efficacy and safety of combined oral contraceptives (COCs) for the prevention of endometrial hyperplasia (EH) in women of reproductive age. The possibilities and perspectives of using COCs for the prevention of EH according to scientific data on the grounds of evidence-based medicine over the past 5 years were considered. It was proven that expanding the range of effective treatment options for EH allows adapting treatment to patients’ needs and offers a personalized approach to their management. Conclusion. Gestodene-containing COCs are an effective and safe method for the prevention of non-atypical EH, carrying a wide range of therapeutic benefits associated with reliable contraceptive capacity and favorable fertility prognosis, especially in young women. Key words: endometrial hyperplasia, COCs, gestodene, polycystic ovary syndrome
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
